Search CTL/CD8+ T-Cell Epitope Database

Found 5 matching records:

Displaying record number 58608

Download this epitope record as JSON.

HXB2 Location	Pol(918-926) Integrase(203-211) DNA(4836..4862)	Pol Epitope Map
Author Location	Integrase(202-212)
Epitope	`IIATDIQTK`	Epitope Alignment
Epitope Name	IK9
Subtype	B
Species (MHC/HLA)	human(A*11)
Immunogen	HIV-1 infection
Country	China
Experimental methods
Keywords	optimal epitope, A-list

Notes

C. Brander noted this as an optimal A*11 epitope based on data from Wang2007.

References

Llano2019 Anuska Llano, Samandhy Cedeño, Sandra Silva Arrieta, and Christian Brander. The 2019 Optimal HIV CTL Epitopes Update: Growing Diversity in Epitope Length and HLA restriction. 2019. Show all entries for this paper.

Displaying record number 61874

Download this epitope record as JSON.

HXB2 Location	Pol(918-926) Integrase(203-211) DNA(4836..4862)	Pol Epitope Map
Author Location
Epitope	`IIATDIQTK`	Epitope Alignment
Epitope Name	IK9
Subtype	B
Species (MHC/HLA)	human(A*11)
Immunogen	HIV-1 infection, vaccine
Country	Japan
Experimental methods	CD8 T-cell Elispot - IFNγ, Intracellular cytokine staining, Other
Keywords	vaccine-induced immune responses

Notes

The candidate tHIVconsvX vaccine is composed of 6 conserved Gag and Pol regions. Specific T cells - from 200 ART-naive, infected Japanese subjects previously exposed to the tHIVconsvX vaccine - that have the ability to supress HIV-1 replication were identified as recognizing 6 Pol epitopes. 6/25 epitopes (comprising 20 known and 5 novel mapped epitopes) remain associated with positive clinical outcome.
A*11-restricted Pol epitope IIATDIQTK was found in 15-mer peptide pair C362/363. While 1/221 Japanese subjects responded to the epitope, 1/20 HLA-carrying and 10/20 non-HLA tested responders reacted to this epitope in EliSpot.

References

Zou2019 Chengcheng Zou, Hayato Murakoshi, Nozomi Kuse, Tomohiro Akahoshi, Takayuki Chikata, Hiroyuki Gatanaga, Shinichi Oka, Tomáš Hanke, and Masafumi Takiguchi. Effective Suppression of HIV-1 Replication by Cytotoxic T Lymphocytes Specific for Pol Epitopes in Conserved Mosaic Vaccine Immunogens. J. Virol., 93(7), 1 Apr 2019. PubMed ID: 30674626. Show all entries for this paper.

Displaying record number 55244

Download this epitope record as JSON.

HXB2 Location	Pol(918-926) Integrase(203-211) DNA(4836..4862)	Pol Epitope Map
Author Location	Integrase(202-212)
Epitope	`IIATDIQTK`	Epitope Alignment
Epitope Name	IK9
Subtype	B
Species (MHC/HLA)	human(A11)
Immunogen	HIV-1 infection
Country	China
Experimental methods	CD8 T-cell Elispot - IFNγ, Intracellular cytokine staining, Other
Keywords	assay or method development, optimal epitope

Notes

HLA-A11-restricted CTL epitopes in 2 male Han Chinese subjects (one ART naive and one receiving HAART) were determined. A novel epitope was discovered and 5 other putative epitopes confirmed using 425 overlapping peptides spanning the entire HIV-1 clade B proteome. By employing intracellular cytokine staining, the authors developed a new method of mapping optimal epitopes and defining their HLA restriction efficiently. In spite of its being the most common HLA type in China, A*11-restricted epitopes were recognized less frequently than other epitopes, and A*11-restricted responses formed a mean of only 13% of the responses against HIV.
This novel epitope, IIATDIQTK (IK9), was detected and confirmed within overlapping peptides SAGERIVDIIATDIQTK and DIIATDIQTKELQKQITK.

References

Wang2007 Shaoyang Wang, Yongtao Sun, Song Zhai, Yan Zhuang, Shuguang Zhao, Whenzhen Kang, Xinhong Li, Dedong Huang, Xu G. Yu, Bruce D. Walker, and Marcus A. Altfeld. Identification of HLA-A11-Restricted HIV-1-Specific Cytotoxic T-Lymphocyte Epitopes in China. Curr. HIV Res., 5(1):119-128, Jan 2007. PubMed ID: 17266563. Show all entries for this paper.

Displaying record number 62854

Download this epitope record as JSON.

HXB2 Location	Pol(918-926) Integrase(203-211) DNA(4836..4862)	Pol Epitope Map
Author Location	Integrase(203-211)
Epitope	`IIATDIQTK`	Epitope Alignment
Epitope Name	IK9
Subtype	B, C
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, engineered
Experimental methods	Other, Relative replication capacity assay
Keywords	acute/early infection, HLA associated polymorphism, chronic infection, protective allele

Notes

The in vitro replicative capacity (RC) of recombinant subtype B NL4-3 viruses expressing subtype C RT-integrase sequences derived from recently infected patients correlated positively with log subsequent VL set point and a higher rate of CD4 decline, while the RC of NL4-3 recombinants expressing subtype C RT-integrase sequences derived from chronically infected patients correlated positively with log VL but negatively with CD4 count. Protective & risk HLA alleles were associated with lower and higher RC values, respectively, and the number of HLA-associated polymorphisms in RT correlated positively with RC while the inverse was observed for integrase. About 90% of RT-integrase polymorphisms significantly associated with altered RC occurred inside or within 5 aa of A-list epitopes (LANL HIV Database).
Integrase polymorphism K211R and subtype C consensus K211 were associated with altered RC and are located within well-defined epitope IIATDIQTK, IY9, known to bind to A*11.
K211R occurred in 53 participant-derived recombinant viruses with a median RC of 0.89, while 414 analogous viruses with consensus K211 had a median RC of 0.93, relative to unmodified NL4-3.

References

Ojwach2018 Doty B. A. Ojwach, Daniel MacMillan, Tarylee Reddy, Vladimir Novitsky, Zabrina L. Brumme, Mark A. Brockman, Thumbi Ndung'u, and Jaclyn K. Mann. Pol-Driven Replicative Capacity Impacts Disease Progression in HIV-1 Subtype C Infection. J. Virol., 92(19), 1 Oct 2018. PubMed ID: 29997209. Show all entries for this paper.

Displaying record number 62897

Download this epitope record as JSON.

HXB2 Location	Pol(918-926) Integrase(203-211)	Pol Epitope Map
Author Location	Integrase(203-211)
Epitope	`IIATDIQTK`	Epitope Alignment
		Show epitope variants
Epitope Name	IK9
Subtype	B, C
Species (MHC/HLA)	human
Immunogen	HIV-1 infection, engineered
Experimental methods	Other, Relative replication capacity assay
Keywords	vaccine antigen design

Notes

Single nucleotide mutations were introduced onto a patient-derived subtype C reverse transciptase (RT)-integrase sequence (SK-278, 98.2% similar to consensus C) on a subtype B NL4-3ΔRT-integrase backbone and assessed for their impact on in vitro viral replicative capacity (RC) in a GFP-based assay. Structural modeling of the RT mutations that mediated the greatest RC reductions (A158S, V241I, & I257V) provided insight into functional consequences.
Relative to NL4-3 recombinant virus encoding wild-type SK-278 RT-integrase, the introduction of integrase mutation I208M mediated ˜12% reduction in RC while the introduction of I201V or I208L did not mediate a significant reduction in RC.
In SK-278, residue 208 is located within best-defined epitope IIATDIQTK (IK9, known to bind A*11) while I201V flanks IIATDIQTK and is located within overlapping epitope GERIIDII.

References

Ojwach2021 Doty B. A. Ojwach, Paradise Madlala, Michelle Gordon, Thumbi Ndung'u, and Jaclyn K. Mann. Vulnerable targets in HIV-1 Pol for attenuation-based vaccine design. Virology, 554:1-8 doi, Feb 2021. PubMed ID: 33316731 Show all entries for this paper.